Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Mathew C. Casimiro 1, 4 , Gabriele Di Sante 1, 4 , Marco Crosariol 1, 4 , Emanuele Loro 1, 4 , William Dampier 5 , Adam Ertel 1, 4 , Zuoren Yu 1, 4 , Elizabeth A. Saria 6 , Alexandros Papanikolaou 6 , Zhiping Li 1, 4 , Chenguang Wang 3, 4 , Sankar Addya 1, 4 , Michael P. Lisanti 3, 4 , Paolo Fortina 1, 4 , Robert D. Cardiff 7 , Aydin Tozeren 5 , Erik S. Knudsen 1, 4 , Andrew Arnold 6 , Richard G. Pestell 1, 2, 4, 8 1 Departments of Cancer Biology, Thomas Jefferson University & Hospital, Philadelphia, PA 19107, USA 2 Medical Oncology, Thomas Jefferson University & Hospital, Philadelphia, PA 19107, USA 3 Stem Cell and Regenerative Medicine, Thomas Jefferson University & Hospital, Philadelphia, PA 19107, USA 4 Sidney Kimmel Cancer Center, Philadelphia, PA 19107, USA 5 Center for Integrated Bioinformatics, School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA 19104, USA 6 Center for Molecular Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA 7 Department of Pathology and Laboratory Medicine, UC Davis Center for Comparative Medicine, University of California, Davis CA 95616, USA 8 Kazan Federal University, Kazan 420008, Republic of Tatarstan, Russian Federation Correspondence to: Richard G. Pestell, e-mail: Richard.Pestell@Jefferson.edu Keywords: Cyclin D1, breast cancer, chromosomal instability Received: January 14, 2015 Accepted: January 31, 2015 Published: March 25, 2015 ABSTRACT Cyclin D1 is an important molecular driver of human breast cancer but better understanding of its oncogenic mechanisms is needed, especially to enhance efforts in targeted therapeutics. Currently, pharmaceutical initiatives to inhibit cyclin D1 are focused on the catalytic component since the transforming capacity is thought to reside in the cyclin D1/CDK activity. We initiated the following study to directly test the oncogenic potential of catalytically inactive cyclin D1 in an in vivo mouse model that is relevant to breast cancer. Herein, transduction of cyclin D1 –/– mouse embryonic fibroblasts (MEFs) with the kinase dead KE mutant of cyclin D1 led to aneuploidy, abnormalities in mitotic spindle formation, autosome amplification, and chromosomal instability (CIN) by gene expression profiling. Acute transgenic expression of either cyclin D1 WT or cyclin D1 KE in the mammary gland was sufficient to induce a high CIN score within 7 days. Sustained expression of cyclin D1 KE induced mammary adenocarcinoma with similar kinetics to that of the wild-type cyclin D1. ChIP-Seq studies demonstrated recruitment of cyclin D1 WT and cyclin D1 KE to the genes governing CIN. We conclude that the CDK-activating function of cyclin D1 is not necessary to induce either chromosomal instability or mammary tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
The UCSC genome browser and associated tools
Kuhn, R. M., Haussler, D., & Kent, W. J. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs038 · Cited by 883
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers
Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F., Zagozdzon, A., Goswami, T., Wang, Y. E., Clark, A. B., et al. (2011) · Nature · doi:10.1038/nature10155 · Cited by 333
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329
Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen
Bienvenu, F., Jirawatnotai, S., Elias, J. E., Meyer, C. A., Mizeracka, K., Marson, A., Frampton, G. M., Cole, M. F., Odom, D. T., Odajima, J., et al. (2010) · Nature · doi:10.1038/nature08684 · Cited by 276
ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice
Casimiro, M. C., Crosariol, M., Loro, E., Ertel, A., Yu, Z., Dampier, W., Saria, E. A., Papanikolaou, A., Stanek, T. J., Li, Z., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60256 · Cited by 115
Self-citation
Cited by
The double dealing of cyclin D1
Tchakarska, G., & Sola, B. (2020) · Cell Cycle · doi:10.1080/15384101.2019.1706903 · Cited by 278
“Casimiro and coworkers showed, in several mouse models of breast cancer, that cyclin D1, independently of CDK4/6, regulated a transcriptional program governing chromosome instability at the level of local chromatin [10,89].”
InfluentialTigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Brett, J. O., Arjona, M., Ikeda, M., Quarta, M., de Morrée, A., Egner, I. M., Perandini, L. A., Ishak, H. D., Goshayeshi, A., Benjamin, D. I., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0190-0 · Cited by 162
Metadata
- Authors
- Casimiro, M. C., Di Sante, G., Crosariol, M., Loro, E., Dampier, W., Ertel, A., Yu, Z., Saria, E. A., Papanikolaou, A., Li, Z., Wang, C., Addya, S., Lisanti, M. P., Fortina, P., Cardiff, R. D., Tozeren, A., Knudsen, E. S., Arnold, A., & Pestell, R. G.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-03-25
- Volume
- 6
- Issue
- 11
- Pages
- 8525-8538
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2120861858
- Cited by
- 45
- References
- 9
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.